Purpose Evidence on the association between coffee consumption and prostate cancer risk is inconsistent; furthermore, few studies have examined the relationship between coffee consumption and fatal prostate cancer. The aim of this study was to investigate whether coffee intake is associated with the risk of overall and fatal prostate cancer. Methods We conducted a prospective analysis among 288,391 men in the National Institutes of Health AARP Diet and Health Study who were between 50 and 71 years old at baseline in 1995-1996. Coffee consumption was assessed at baseline. Cox proportional hazards models were used to calculate the age-and multivariable-adjusted hazard ratios (HR)s and 95 % confidence intervals (CIs). Results Over 11 years of follow-up, 23,335 cases of prostate cancer were ascertained, including 2,927 advanced and 917 fatal cases. Coffee consumption was not significantly associated with prostate cancer risk. The multivariable-adjusted HRs (95 % CI), comparing those who drank six or more cups per day to nondrinker, were as follows: 0.94 (0.86-1.02), p trend = 0.08 for overall prostate cancer, 1.13 (0.91-1.40), p trend = 0.62 for advanced prostate cancer, and 0.79 (0.53-1.17), p trend = 0.20 for fatal prostate cancer. The findings remained nonsignificant when we stratified by prostate-specific antigen testing history or restricted to nonsmokers. Conclusions We found no statistically significant association between coffee consumption and the risk of overall, advanced, or fatal prostate cancer in this cohort, though a modest reduction in risk could not be excluded.
risk of prostate cancer through the antioxidant and antiinflammatory effects of its beneficial components including lignans, phytoestrogens, and chlorogenic acids [4] [5] [6] . Coffee has also been associated with lower levels of IGF-1 and circulating sex hormones which are associated with prostate cancer progression [7, 8] . Epidemiological evidence of the relationship between coffee consumption and prostate cancer is inconsistent. Several prospective studies found no significant association between coffee intake and risk of prostate cancer [9] [10] [11] [12] . However, many of these adjusted for only a few confounding factors and lacked information on disease stage and grade. Adjustment for smoking is particularly important since smoking is linked with increased coffee intake in many populations and is independently associated with higher risk of prostate cancer mortality [13, 14] . A meta-analysis of five cohort studies reported an inverse association between coffee consumption and overall prostate cancer risk, with a summary estimate of 0.76 [95 % confidence interval (CI) 0.61, 0.98] for highest drinkers versus. non/low drinkers [15] . A recent study reported a marked decrease in risk of lethal (but not overall) prostate cancer [8] . The aim of our analysis was to examine the association between coffee consumption and risk of fatal, advanced, and overall prostate cancer in a large cohort with long follow-up and information on multiple potential confounders.
Methods

Study population
The NIH-AARP Diet and Health Study was initiated in 1995-1996, when AARP members aged 50-71 years old residing in six US states (California, Florida, Louisiana, New Jersey, North Carolina, and Pennsylvania) and two metropolitan areas (Atlanta and Detroit) responded to a questionnaire eliciting information on dietary behaviors, demographic characteristics, and other health-related information (n = 566,398) [16] . Completion of the selfadministered questionnaire was considered to imply informed consent to participate in the study. In a subsequent mailed questionnaire (1996-1997, 69 % response rate), participants reported their history of prostate-specific antigen (PSA) testing and digital rectal examinations during the previous 3 years. For our analyses, we excluded 14,495 men whose questionnaires were completed by others, as well as 27,270 with cancer other than nonmelanoma skin cancer at baseline, 626 with self-reported kidney failure, 2,575 who reported extreme intake of total energy (exceeding twice the interquartile ranges of logtransformed intake), 1,273 with missing coffee intake information, and 5,036 who died in the first 2 years of follow-up, leaving an analysis dataset of 288,391 men. The NIH-AARP Diet and Health Study was approved by the Special Studies Institutional Review Board of the National Cancer Institute.
Assessment of exposure
At baseline, participants completed a 124-item food frequency questionnaire that assessed dietary intake over the previous 12 months, including caffeine containing drinks such as coffee, tea and soft drinks [17] . Consumption was assessed in frequency categories ranging from 0 to 6 or more cups per day, and almost 90 % of coffee drinkers provided information on whether they drank caffeinated or decaffeinated coffee more than half the time. The questionnaire also included foods that contain small amounts of caffeine. Total daily caffeine intake was calculated based on the food items, portion sizes, and nutrient database constructed using the US Department of Agriculture's 1994-1996 Continuous Survey of Food Intake by Individuals [18] . The FFQ was validated in a subset of the study population using two nonconsecutive 24-h recalls [19] , and the correlation coefficient for coffee consumption between the two assessment methods was 0.8 [20] .
Ascertainment and classification of prostate cancer Study participants were followed by means of linkage to the National Change of Address database maintained by the US Postal Service, specific change-of-address requests from participants, and updated addresses returned during other mailings. Incident prostate cancer cases were identified through linkage with eleven state cancer registry databases (eight original and three additional states-Arizona, Nevada, and Texas). Vital status was assessed by periodic linkage to the Social Security Administration Death Master File on deaths in the US, follow-up searches of the National Death Index Plus for participants who matched to the Social Security Administration Death Master File, cancer registry linkage, questionnaire responses, and responses to other mailings. Details on the cohort design and maintenance have been described previously [16] .
Information on prostate cancer stage was obtained from the registries. We defined advanced cases as those whose cancer had spread beyond the prostate, with a clinical classification of T3-T4, N1, or M1 according the tumornode-metastasis classification system or those who subsequently died of prostate cancer during follow-up. Fatal cases, a subset of advanced cases, were those who died of prostate cancer during follow-up. Nonadvanced cases were those involving the prostate gland only (classification of T1a-T2b, N0, and M0).
Statistical analysis
Person-years of follow-up was calculated from return of baseline questionnaire to diagnosis of any cancer, move out of the cancer registry area, death, or the end of follow-up, whichever came first. Participants were followed for incidence until 31 December 2006 and for death until 31 December 2008. We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95 % CI for coffee intake categories (none, \1, 1, 2-3, 4-5, and C6 cups/day). The proportional hazards assumption was tested and confirmed by modeling an interaction of follow-up time with coffee consumption. Tests of linear trend across categories of coffee consumption were performed by modeling the categories as continuous variables using the median intake for each category.
The multivariate models were adjusted for potential confounding by prostate cancer risk factors previously identified in this cohort and in other studies including race (white, black, other), age (continuous), height (quartiles), body mass index (BMI) (\18. 2 ), physical activity (never or rarely, 1-3 times per month, 1-2 times per week, 3-4 times per week, or 5? times per week), smoking status (never, past quit [10 years, past quit \10 years B20 cigarettes/day, past quit \10 years [20 cigarettes/day, current B20 cigarettes/day, current [20 cigarettes/day), history of diabetes (yes or no), family history of prostate cancer (yes or no), PSA testing (yes, no, unknown), intake of tomato sauce, alpha-linolenic acid, and total energy intake (all continuous). Other covariates considered for adjustment but not kept in the final models were intake of calcium, alcohol, processed meat supplemental vitamin E use, and multivitamin use. For participants with missing data (generally \5 %), an indicator variable was included in the models. In order to minimize the possible effect of change in coffee consumption due to undiagnosed disease, we excluded deaths that occurred during the first 2 years of follow-up from our analysis.
In further analysis, we stratified by PSA screening history to examine whether results were influenced by differences in screening behavior according to coffee consumption patterns. We also investigated the role of caffeine versus other components of coffee by estimating the hazard ratios for regular and decaffeinated coffee separately.
Since smoking is a risk factor for fatal prostate cancer and also often linked to increased coffee consumption, we conducted additional analysis, restricted the analysis to never smokers or those who had quit for at least 10 years to fully control for the smoking effect. All analyses were conducted on SAS software, version 9.1. Statistical tests were two-sided, and p values of less than 0.05 were considered to be statistically significant.
Results
Over 11 years of follow-up (median 10.5 years), 23,335 cases of prostate cancer were ascertained, including 2,927 advanced and 917 fatal cases. Approximately 9 % of the participants reported drinking no coffee and 4 % reported drinking six or more cups per day (Table 1 ). Compared to men who did not drink coffee, men who drank the most coffee were more likely to be current smokers, less likely to be physically active, and less likely to report a history of PSA testing at baseline. About two-thirds of coffee drinkers reported drinking mostly caffeinated coffee.
In the multivariate models, we observed no association between coffee consumption and overall prostate cancer (HR: 0.94, 95 % CI 0.86-1.02, p trend = 0.08).
There was no significant association between coffee consumption and advanced prostate cancer (HR: 1.13, 95 % CI 0.91-1.40, p trend = 0.62) or fatal prostate cancer (HR: 0.79, 95 % CI 0.53-1.17, p trend = 0.20), comparing those who drank more than six cups per day with nondrinkers ( Table 2 ). The HR was 0.77 (0.59-1.02) for four or more cups versus none. We conducted a sensitivity analysis using low coffee drinkers (1 or less cups per day) as the referent group. The HR and 95 % CI comparing men who consumed Bcup/day to C6 cups/day were 0.92 (0.85-0.99) for total prostate cancer and 0.90 (0.63-1.29) for fatal prostate cancer.
When associations were examined and stratified by recent PSA screening (provided by 69 % of the cohort), similar results were observed for men with and without PSA test. We combined the two top categories (4-5 cups and 6 or more cups per day) for sufficient numbers. The HR for total prostate cancer, comparing those who drank 4 or more cups per day with nondrinkers were 1.01 (95 % CI 0.93-1.09) for men who had a prior PSA test and 1.01 (95 % CI 0.85-1.19) for those who did not. For fatal prostate cancer, the HR (4 or more cups per day versus none) was 0.78 (95 % CI 0.50-1.23) for those with a prior PSA test and 0.94 (95 % CI 0.47-1.88) for those without a prior PSA.
Since current cigarette smoking was significantly associated with fatal prostate cancer, and highest among men who drank the most coffee, we restricted the analysis to nonsmokers (never smokers and those who quit more than 10 years earlier) to fully adjust for its effects. We chose this categorization based on evidence that former smokers who have quit for at least 10 years have prostate cancer mortality risk similar to those who never smoked [13] . With the effects of smoking fully controlled in these models, the age-and multivariate-adjusted HR, particularly for fatal prostate cancer, were quite similar, but the associations remained nonsignificant for overall, advanced, and fatal prostate cancer (Table 3) .
We also evaluated the association for regular (caffeinated) versus decaffeinated coffee separately and saw no differences in associations between the two groups. There was also no statistically significant association between total caffeine intake and risk of overall, advanced, or fatal prostate cancer (data not shown).
Discussion
In this large prospective cohort study, we found no statistically significant association between coffee consumption and the risk of overall prostate cancer, advanced prostate cancer, or fatal prostate cancer. The associations remained nonsignificant even after we restricted the analysis to nonsmokers. The results were similar in those who reported a recent PSA screening and those who did not.
Coffee consumption was inversely associated with total prostate cancer in the age-adjusted models but not in the multivariate-adjusted models. Differential PSA screening in men consuming the most coffee compared to nondrinkers could explain this as the percentage of men reporting PSA testing at baseline was 44 % in nondrinkers versus 37 % in men consuming six or more cups of coffee per day. In an analysis stratified by PSA screening history, the age-adjusted hazard ratios were not statistically significant across the strata.
Findings from past studies on coffee consumption and the risk of prostate cancer have been inconsistent with most, though not all studies, reporting null results [9] [10] [11] [12] . Most of these studies examined the risk of overall prostate cancer. In the post-PSA era, there is large variation in the biological potential of cases and a large number of latent screen-detected cases will not progress to clinical significance even in the absence of treatment [21] . Different factors may affect prostate cancer at various stages of progression; therefore, associations may differ by disease stage [6] . It is likely that the factors associated with the development of indolent tumors may be different from those associated with tumors that are likely to advance to metastatic stages [22] . By focusing solely on total incident cases, the studies may have missed an association that is specific to lethal disease. Studies examining the association with prostate cancer aggressiveness have also reported differing findings [8, 23, 24] . A retrospective cohort reported no significant association [24] , whereas two other Table 2 Hazard ratios and 95 % confidence intervals of prostate cancer by categories of coffee consumption in the NIH-AARP Diet and Health Study Categories of total coffee intake (cups/day) studies reported an inverse association between high-grade prostate cancer and coffee consumption [8, 23] .
Only a few studies have examined the association of coffee with lethal or fatal prostate cancer [8, 25, 26] . Two studies reported no statistically significant associations between coffee consumption and prostate cancer mortality. The Lutheran cohort (n = 149 cases) found no association comparing C5 cups versus \3 cups per day [26] . Phillips et al. [25] reported a nonsignificant hazard ratio comparing C2 cups to none (n = 98 cases). However, these studies had narrow range of coffee intake, small number of cases and adjusted for few potential confounders that did not include smoking [25, 26] . In contrast, the Health Professionals' Follow-up Study (HPFS) found a 60 % lower risk of lethal prostate cancer among men who drank six or more cups of coffee per day compared to nondrinkers (HR: 0.40 95 % CI 0.22-0.75) [8] .
Study differences may explain the discrepancy between our findings and those in HPFS [8] . In an effort to compare the findings from these two studies, we conducted an analysis in HPFS limiting to conditions in the NIH-AARP study, that is, baseline at 1996, coffee consumption assessed once at baseline, and follow-up through 2006. Under these conditions, the results in HPFS were not statistically significant, similar to our findings in the NIH-AARP cohort. The hazard ratios (95 % CI) were 0.90 (0.78-1.04), p trend 0.18 for total prostate cancer and 1.22 (0.64-2.33), p trend 0.98 for fatal prostate cancer, comparing those who drank four or more cups per day to nondrinkers. The findings remained nonsignificant when stratified by PSA or restricted to nonsmokers. These results may well suggest that longer follow-up, as is the case in HPFS, is important in the relationship between coffee and prostate cancer, and the results from the NIH-AARP cohort may not be at odds with the HPFS study findings. It is possible that any potential latent period between exposure and disease might not be represented in the 10-year follow-up.
Our study had some limitations. Coffee consumption was assessed using a single baseline questionnaire. As such, we were unable to account for any dietary changes during follow-up and likely misclassified those who changed their intake during follow-up. Repeated assessment of coffee consumption over the 11-year follow-up period could have reduced random within-person measurement error [27] . It is possible that nondifferential measurement error in the assessment of coffee could have biased our estimates toward the null. It is also possible that confounding by poorly measured confounders could have affected our findings masking the true association.
Despite this, our study had several strengths including the prospective design, and large number of cases ascertained over a long follow-up period that allowed us to examine the association by disease stage. We also had information on a variety of potential confounding factors. The multivariate models are adjusted for age, race, height, BMI, physical activity, history of diabetes, family history of prostate cancer, PSA testing, intakes of tomato sauce, alpha-linolenic acid, and total energy intake. Cases with missing stage are included in the total prostate cancer count but not in the subtypes BMI body mass index HR hazard ratio NIH National Institutes of Health PSA prostate-specific antigen
In conclusion, our findings indicate no significant association between coffee consumption assessed at baseline, and risk of overall, advanced, or fatal prostate cancer in this large prospective cohort. However, we cannot exclude a modest inverse association. Further studies on coffee and prostate cancer in similarly large prospective cohorts with long follow-up time may shed more light on the association.
